190 related articles for article (PubMed ID: 1719230)
1. Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus.
Hansen JE; Nielsen C; Arendrup M; Olofsson S; Mathiesen L; Nielsen JO; Clausen H
J Virol; 1991 Dec; 65(12):6461-7. PubMed ID: 1719230
[TBL] [Abstract][Full Text] [Related]
2. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions.
Callahan LN; Phelan M; Mallinson M; Norcross MA
J Virol; 1991 Mar; 65(3):1543-50. PubMed ID: 1995952
[TBL] [Abstract][Full Text] [Related]
3. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
[TBL] [Abstract][Full Text] [Related]
4. Characterization of monoclonal antibodies identifying type and strain-specific epitopes of human immunodeficiency virus type 1.
Robert V; Resnicoff M; Chermann JC; Devaux C
Mol Cell Biochem; 1991 Apr; 102(2):115-23. PubMed ID: 1715507
[TBL] [Abstract][Full Text] [Related]
5. Enzyme immunoassay (ELISA) for the evaluation of antibodies directed to the CD4 receptor-binding site of the HIV gp120 molecule.
Hinkula J; Gidlund M; Persson C; Osterhaus A; Wahren B
J Immunol Methods; 1994 Sep; 175(1):37-46. PubMed ID: 7523525
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
[TBL] [Abstract][Full Text] [Related]
7. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.
Bolmstedt A; Sjölander S; Hansen JE; Akerblom L; Hemming A; Hu SL; Morein B; Olofsson S
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):213-20. PubMed ID: 8673525
[TBL] [Abstract][Full Text] [Related]
8. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120.
Akerblom L; Hinkula J; Broliden PA; Mäkitalo B; Fridberger T; Rosen J; Villacres-Eriksson M; Morein B; Wahren B
AIDS; 1990 Oct; 4(10):953-60. PubMed ID: 1702001
[TBL] [Abstract][Full Text] [Related]
10. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120.
Matsushita S; Matsumi S; Yoshimura K; Morikita T; Murakami T; Takatsuki K
J Virol; 1995 Jun; 69(6):3333-40. PubMed ID: 7538171
[TBL] [Abstract][Full Text] [Related]
12. Characterization of monoclonal antibodies to human immunodeficiency virus type 2 envelope glycoproteins.
Traincard F; Rey-Cuillé MA; Huon I; Dartevelle S; Mazié JC; Benichou S
AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1659-67. PubMed ID: 7888225
[TBL] [Abstract][Full Text] [Related]
13. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.
Trkola A; Pomales AB; Yuan H; Korber B; Maddon PJ; Allaway GP; Katinger H; Barbas CF; Burton DR; Ho DD
J Virol; 1995 Nov; 69(11):6609-17. PubMed ID: 7474069
[TBL] [Abstract][Full Text] [Related]
14. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
Moulard M; Phogat SK; Shu Y; Labrijn AF; Xiao X; Binley JM; Zhang MY; Sidorov IA; Broder CC; Robinson J; Parren PW; Burton DR; Dimitrov DS
Proc Natl Acad Sci U S A; 2002 May; 99(10):6913-8. PubMed ID: 11997472
[TBL] [Abstract][Full Text] [Related]
15. Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4.
Moore JP; McKeating JA; Jones IM; Stephens PE; Clements G; Thomson S; Weiss RA
AIDS; 1990 Apr; 4(4):307-15. PubMed ID: 2190605
[TBL] [Abstract][Full Text] [Related]
16. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.
Choudhry V; Zhang MY; Sidorov IA; Louis JM; Harris I; Dimitrov AS; Bouma P; Cham F; Choudhary A; Rybak SM; Fouts T; Montefiori DC; Broder CC; Quinnan GV; Dimitrov DS
Virology; 2007 Jun; 363(1):79-90. PubMed ID: 17306322
[TBL] [Abstract][Full Text] [Related]
17. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
Kang CY; Hariharan K; Nara PL; Sodroski J; Moore JP
J Virol; 1994 Sep; 68(9):5854-62. PubMed ID: 7520095
[TBL] [Abstract][Full Text] [Related]
18. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.
Stamatatos L; Lim M; Cheng-Mayer C
AIDS Res Hum Retroviruses; 2000 Jul; 16(10):981-94. PubMed ID: 10890360
[TBL] [Abstract][Full Text] [Related]
19. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
Mascola JR; Snyder SW; Weislow OS; Belay SM; Belshe RB; Schwartz DH; Clements ML; Dolin R; Graham BS; Gorse GJ; Keefer MC; McElrath MJ; Walker MC; Wagner KF; McNeil JG; McCutchan FE; Burke DS
J Infect Dis; 1996 Feb; 173(2):340-8. PubMed ID: 8568294
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]